Mesenchymal stem cells injected intravenously do not engraft. They circulate, they lodge transiently in the lungs and spleen, and within weeks they are cleared. By conventional logic, a therapy that disappears should produce effects that disappear with it. The cells are gone; the benefit should follow.
Longeveron's phase 2b trial (Cell Stem Cell 2026, n=148) tested laromestrocel — bone marrow–derived allogeneic MSCs — in frail elderly patients. The highest-dose group walked 63.4 meters farther in the six-minute walk test at nine months (95% CI: 17.1–109.6 m; p = 0.0077). Not at one month. Not at three. At nine — months after the cells themselves were gone. The dose-response curve was monotonic and the biomarker response was specific: decreasing soluble TIE2, a marker of vascular remodeling, correlated with functional improvement.
The mechanism is catalytic, not structural. The cells don't replace aged tissue. They modulate the immune and vascular environment during their brief transit — suppressing inflammatory signaling, promoting angiogenesis, altering the secretome of resident cells — and then disappear. The cascade they trigger continues without them. The nine-month peak reflects the timescale of tissue remodeling, not the timescale of cell survival. The therapy works like a match, not a furnace: the flame is brief; the fire it starts is not.
The general principle: a transient input can produce a lasting output when the input triggers a self-sustaining process rather than performing the work directly. The persistence of the effect is evidence of mechanism, not of presence. And the delay between intervention and peak effect — the gap where the cells are gone but the benefit is still growing — is the signature of catalysis. The signal is absent. The consequence is not.